Maxine Taylor

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2

Josie A. Blackie, Jackie C. Bloomer, Murray J. B. Brown et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 129 citations · Full text

Lipoprotein-associated Phospholipase A2, Biochemistry, Potent Inhibitor +8

Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds

Melanie Z. Sakatis, Melinda J. Reese, Andrew W. Harrell et al. · Chemical Research in Toxicology · 2012 · 120 citations

System Pharmacology, Vitro Bioactivation Data, Pharmacodynamic Modeling +21

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Pamela L. St. Jean, Zhengyu Xue, Nick Carter et al. · Malaria Journal · 2016 · 99 citations · Full text

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

Inge Sutanto, Amin Soebandrio, Lenny L. Ekawati et al. · The Lancet Infectious Diseases · 2023 · 42 citations · Full text

Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure

Dilek Iusuf, Anita van Esch, Michael Hobbs et al. · Molecular Pharmacology · 2013 · 36 citations